Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab

Dermatology

Volumn 218, Issue 1, 2008, Pages 79-83

  Yawalkar, Nikhil ^a   Hunger, Robert E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adalimumab; Biologicals; Infliximab; Pustular psoriasis, treatment; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ETRETIN; HLA DR ANTIGEN; INFLIXIMAB; METHOTREXATE; METHOXSALEN; STEROID; TACROLIMUS; TAR; TAZAROTENE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D DERIVATIVE;

ADULT; ANTIGEN EXPRESSION; ARTHRALGIA; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DISEASE DURATION; DRUG DOSE INCREASE; DRUG FEVER; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LETTER; MACROPHAGE; MONOTHERAPY; MYALGIA; NEUTROPHIL; PRIORITY JOURNAL; PUSTULE; PUSTULOSIS PALMOPLANTARIS; PUVA; RECURRENT DISEASE; RETREATMENT; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 58149103171     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167802     Document Type: Letter

References (17)

1. Eriksson MO, Hagforsen E, Lundin IP, Michaelsson G: Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol 1998;138:390-398.
2. Enfors W, Molin L: Pustulosis palmaris et plantaris: a follow-up study of a ten-year material. Acta Derm Venereol 1971;51:289-294.
3. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003;49:271-275.
4. Elewski BE: Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 2002;47:796-797.
5. Newland MR, Weinstein A, Kerdel F: Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002;41:449-452.
6. Kasche A, Pfab F, Hein R, Athanasiadis GI, Ollert M, Ring J, Eberlein-Konig B: Severe psoriasis pustulosa palmaris et plantaris (Barber-Konigsbeck) treated successfully with soluble tumour necrosis factor receptor fusion protein (etanercept). J Eur Acad Dermatol Venereol 2007;21:255-257.
7. Schmick K, Grabbe J: Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab). Br J Dermatol 2004;150:367.
8. Weishaupt C, Metze D, Luger TA, Ständer S: Treatment of pustular psoriasis with infliximab. J Dtsch Dermatol Ges 2007;5:397-399.
9. Kazinski K, Joyce KM, Hodson D: The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of Hallopeau. J Drugs Dermatol 2005;4:360-364.
10. Callen JP, Jackson JH: Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatol Treat 2005;16:350-352.
11. Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E: Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol 2005;153:1243-1244.
12. Heymann WR: Tumor necrosis factor inhibitor-induced pustular psoriasis? J Am Acad Dermatol 2007;56:327-329.
13. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, Shojania K, Martinka M, Dutz JP: Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-231.
14. Hassan AS, Kaelin U, Braathen LR, Yawalkar N: Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab. J Am Acad Dermatol 2007; 56: 217-221.
15. Hassan AS, Simon D, Simon HU, Braathen LR, Yawalkar N: Efalizumab-associated papular psoriasis. Arch Dermatol 2007; 143: 900-906.
16. Pitarch G, Sánchez-Carazo JL, Mahiques L, Oliver V: Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology 2008; 216: 312-316.
17. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G: Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9: 1-14.